Sign in to view content

Phase 3 Randomized Studies of Efficacy and Safety of Revakinagene Taroretcel Producing Ciliary Neurotrophic Factor (CNTF) in Macular Telangiectasia Type 2

Emily Y. Chew, MD

Video
Published 2023

Related

First Time Results of VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy
Omer Trivizki, MD, MBA
Updates from the Field
2025
Learnings From the Lampalizumab Chroma and Spectri Phase 3 Trials: Effect of Baseline Characteristics on Geographic Atrophy Progression
Carl D. Regillo, MD
Annual Meeting Talks
2018
Clinical Effects of Blocking Ang-2 and VEGF with Faricimab in the Phase 2 STAIRWAY Trial
Carl J Danzig, MD
Annual Meeting Talks
2020

Category: Retinal Vascular Disease

See more